Comparison of the real-world costs associated with different treatment patterns in adults initiating apremilast or biologics for the treatment of psoriasis

Background: Apremilast, an oral, nonbiologic medication, was approved by the U.S. FDA in 2014 for the treatment of adult patients with active psoriatic arthritis and patients with moderate to severe plaque psoriasis. Treatment patterns in patients with psoriasis initiating apremilast or biologics are well described in the literature. However, cost differences associated with different treatment patterns have not been described in biologic-naive patients initiating apremilast compared with biologics for treatment of psoriasis.